re: IPH.PA

Regarding the insider trading story, this is not involving IPH.PA. Collins is charged with insider trading of Innate Immunotherapeutics of Australia.

Daiichi Sankyo to acquire AMBI for $15 per share cash plus CVR

http://finance.yahoo.com/news/daiichi-sankyo-acquire-ambit-biosciences-230700602.html

The street is actually valuing garbage like Onty, YM Bio or Vical higher than Momenta today. It's a shame.


that's the point. pretty easy to buy or keep holding here.






© 2012 InvestorsHub.Com, Inc.

yes, just short the stock here and then (maybe, if you want) sell the puts on monday. lock in your gain without weekend risk.

very nice..

what did i find offensive? nothing. just trying to understand if ib2011 had seen enough over the years to understand that it's ok for things to go deeper and deeper into discount and profit by it. nothing at all was offensive. i'm just curious. i don't find it uncomfortable or unpleasant at all that MNTA closed at $15.07.

IB2011, how old are you? seriously.

so...progress in M118 program negotiations.

It would be nice if it isn't dead after all.

The whole transaction made no sense, so investor's had to side with the safest assumption which would have been that T-Enox was coming.

Well, some of us investors didn't "side with the safest assumption" and we bought heavily. All good in my book. It was a quite small dilution anyway.

jbog what is with your vendetta against MNTA?

Really. Very tiring. What's so hard to understand about automatic sales?

Shea mentioned that has been recent movement on that. Maybe M118 value is $non-zero?

MNTA short interest (1/31/11 settlement)

MNTA
Momenta Pharmaceuticals, Inc.NASDAQ-GS
Settlement Short Interest Avg Daily Volume Days To Cover
1/31/2011 8,303,068 1,935,575 4.289716
1/14/2011 9,150,934 932,291 9.815534

Read more: http://www.nasdaq.com/aspxcontent/shortinterests.aspx?symbol=MNTA&selected=MNTA#ixzz1DVJi2DUg

It would really be Sandoz' call to launch at-risk, wouldn't it?

The Feb. and March call bid and ask spreads have widened beyond belief.

I knew there was a good reason that the market makers get such generous margin treatments. Nice job guys!

MNTA short interest as of settlement 10/15/10


7.94 million up from 6.97 million (settlement 9/30/10)/

Sounds good to me.

Thumbs down. I agree with you about Grant and also about holding the stock.

He hasn’t been a great CEO in terms of shareholder returns during the past couple of years,
A couple of weeks ago, the most recent time the pps was getting hammered, you threw out the term "regime change" in a post. I'm wondering if it's enough that the CEO owns a lot of shares? Thumbs up or thumbs down on Hugh Grant?

Cramer just stated on his show today while professing his love for TEVA that there couldn't be a generic Copaxone on the market until 2014 at the earliest.

I mean that the data wasn't so good that taxotere needs to go away as a treatment option. Again, that phase II survival data of OGX-011 plus tax from 2009 was impressive (I know, 82 patient trial but it was a randomized controlled trial).

Re: OGXI

Maybe there are a lot of people who think the abiraterone data weren't SO good that OGX-011 plus generic taxotere won't have a place in the treatment mix of advanced PCa. It's worth taking a look at the OGX-011 phase II data from 2009.. 6.5 million shares outstanding, $45 million of cash. Three Phase III trials being funded by TEVA.

Interesting Reuters interpretation of MNTA news:

U.S. judge refuses injunction blocking generic version of sanofi's lovenox
blood thinner
* U.S. judge ruling is loss for sellers of generic Novartis AG sandoz
unit, Momenta Pharmaceuticals Inc
((New York Equities Desk; tel: +1 646 223 6000))
((For more news about NOVARTIS click here: ))
Click the link below to go to Reuters Top News Page, a web front page of today's most important business and market news, analysis and commentary.


huh?

What's going on AH in MNTA...16.50 bid..

Teva copy of Lovenox is "close" - Bernstein analyst

Bernstein sees 2nd Lovenox generic in U.S. before end 2010
* Launch of Teva product would lead to quicker price erosion
* Novartis and Momenta launched 1st generic last month
LONDON, Aug 5 (Reuters) - A second generic version of Sanofi-Aventis's blood-clot drug Lovenox is likely to reach the U.S. market this year, intensifying competition and pushing down prices, a leading analyst said on Thursday.
Tim Anderson of Sanford Bernstein said he had information that a second generic, from Teva Pharmaceutical Industries , was "zeroing in on FDA approval, and that this is likely to be on the market in the coming months and before year end".
The U.S. Food and Drug Administration (FDA) approved the first generic copy of Lovenox from Novartis and Momenta Pharmaceuticals last month, dealing a blow to prospects for Sanofi's second-biggest drug, which had worldwide sales of $4 billion last year.
"The importance of this to Sanofi-Aventis is that it means quicker pricing erosion, assuming Teva's product indeed gets approved," Anderson said.
"Our understanding is that Sanofi has been cutting the effective price of its branded Lovenox to maintain share with purchasers, but a new, second generic entrant could frustrate these efforts."
A second entrant would also be bad news for Novartis's generics unit Sandoz and its smaller partner Momenta.
Mounting generic competition to Lovenox and other blockbusters has driven Sanofi to seek acquisitions as part of a strategy to diversify its business and buy in new products.
Sanofi has proposed buying Genzyme for $18.4 billion, and the two sides are discussing the offer, although Genzyme is holding out for more, according to sources familiar with the situation. The companies have not commented.
The complexity of manufacturing Lovenox, known generically as enoxaparin, had raised doubts about when a generic version might be approved. But generic manufacturers have made better progress in copying the medicine than some analysts had expected.
Teva President and CEO Shlomo Yanai said last week after presenting second-quarter results that he had good reason to believe his company was close to getting approval for its generic version of Lovenox, but he gave no timeline.
Anderson said it appeared that other applicants, such as Hospira and Amphastar, were further behind.
Lovenox is used to help prevent deep-vein thrombosis, a condition in which blood clots form in veins deep in the body, especially in the lower leg or thigh.
(Reporting by Ben Hirschler; Editing by Will Waterman)
($1=.7620 Euro)
((ben.hirschler@thomsonreuters.com; Tel: +44 20 7542 5082; Reuters Messaging: ben.hirschler.reuters.com@reuters.net; www.twitter.com/reutersBenHir))

MNTA - I sold 25% of my position today around $26. Leaves me with 4500 shares (basis $9). I echo masterlongevity's sentiments regarding the efforts of DewDiligence. His case regarding this company and its stock was and is completely persuasive. The market has made me into a guy who needs to sell something when anything good happens. I will not sell any more until something changes in a big way. I congratulate all of those who have done well with MNTA.

IDIX halt

Actually, I think many are willing to fork over some more to make sure that much closer to all are afforded the opportunity to have a chance at a standard of care that one would expect from a civilized and rich nation such as the USA. I don't mind spending more and I'm sure I will.

IBD - Obamacare - it's all fine by me and long overdue.

thanks, steveporsche.

DNDN - SAC stake actually 13.1% or so

when you account for all of the SAC related/controlled entities.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6699397

PFE up 65% fom the March lows

I'm happy for it having bought around $14 but it should be pointed out that the S&P 500 us up 71% or so from the March lows, so I guess it's mildly underperforming??

Another 25,000 purchase (12/15-12/16)

by Director Hodgson, 12/16 - 12/16 at $2.12 - $2.15

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6656693

Insider buy 24,613 shares

by Dirctor Thomas Hodgson 12/10 - 12/14 at prices $2.05 - $2.12.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6651561

CLDX CDX-011 at San Antonio

Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast Cancer
-- Data Presented at the San Antonio Breast Cancer Symposium --

NEEDHAM, Mass.--(BUSINESS WIRE)--Dec. 13, 2009-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers. As presented today at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, the primary efficacy endpoint for the study has been met with significant antitumor activity in patients whose tumors express the target GPNMB. In addition, encouraging results were seen in patients with “triple-negative disease” where treatment options are relatively limited due to lack of hormone receptor or HER2-neu expression.

CDX-011 is the first candidate from the Company’s antibody-drug conjugate (ADC) platform, which utilizes fully human monoclonal antibodies to deliver the potent cellular toxin, MMAE, directly to tumor cells by targeting GPNMB. GPNMB is a glycoprotein frequently expressed in a number of tumor types and associated with cancer progression and recurrence. CDX-011 uses the Seattle Genetics MMAE ADC technology, which has established a very promising antitumor effect in advanced clinical studies.

“As seen in this study, treatment with CDX-011 can induce disease regression and stabilization,” said Thomas Davis, M.D., Senior Vice President and Chief Medical Officer of Celldex Therapeutics. “We are very encouraged to see such positive results in patients with triple negative disease – or those with advanced, refractory and heavily pre-treated breast cancers -- where there is a clear unmet medical need. Moving forward, we are planning expanded Phase 2 development focused on patients with tumors expressing GPNMB.”

The Phase 2 study investigated the safety, tolerability and efficacy of CDX-011 in locally advanced or metastatic breast cancer patients who were heavily pre-treated (median of seven prior regimens). The study confirmed the safety of CDX-011 at the pre-defined maximum dose level (1.88 mg/kg) in 6 patients. An additional 28 patients were enrolled as an expanded Phase 2 cohort (for a total of 34 treated patients at 1.88 mg/kg, the Phase 2 dose) to evaluate the progression-free survival (PFS) rate at 12 weeks. As previously seen in melanoma patients, the 1.88 mg/kg dose was well tolerated in this patient population. The primary activity endpoint, which called for at least 5 of 25 (20%) patients in the Phase 2 study portion to be progression-free at twelve weeks, has been met. To date, 9 of 26 (35%) evaluable patients are without progression of disease at twelve weeks.

In addition, at the Phase 2 dose level, 4 of 32 (13%) evaluable patients achieved confirmed or unconfirmed Partial Responses (PR) while 15 of 25 (60%) evaluable patients with measurable disease experienced some reduction in tumor size. GPNMB expression was identified in 10 of 14 (71%) of analyzed tumor samples and treatment with CDX-011 was associated with improved outcomes in all activity parameters in patients whose tumors expressed GPNMB. Notably, in patients who received the Phase 2 dose and whose tumors expressed GPNMB, 2 of 7 (29%) had confirmed Partial Responses, 5 of 7 (71%) had decreases in tumor size, and all 7 achieved at least stable disease with duration from 17.3 to 26.9 weeks. The median PFS in all patients was 9.1 weeks, but in patients whose tumors expressed GPNMB, median PFS was 18.3 weeks, compared to median PFS of 5.9 weeks for patients whose tumors did not express GPNMB. In patients with triple negative disease, 5 of 7 (71%) analyzed samples expressed GPNMB, 7 of 9 (78%) evaluable patients had tumor shrinkage, and the median PFS for these patients was 17.9 weeks.

About CDX-011

CDX-011 (formerly CR011-vcMMAE) is an antibody-drug conjugate (ADC) being developed by Celldex Therapeutics, Inc. that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics, Inc. The ADC is designed to be stable in the bloodstream. Following intravenous administration, CDX-011 targets and binds to GPNMB, a specific protein that is predominantly expressed in cancerous tumors, including melanoma, breast cancer and gliomas. Upon internalization into the targeted cell, CDX-011 is designed to release MMAE from CR011 to produce a cell-killing effect. CDX-011 is currently completing two Phase 2 trials assessing the safety and efficacy in the treatment of melanoma and for the treatment of metastatic breast cancer, and in a Phase 1 trial to evaluate the safety and activity of alternate dosing schedules.

MNTA - I noticed 1000 Dec 15 calls traded in MNTA yesterday at something like 0.13. I thought that was interesting.

HCV quiz-
How about Bristol-Myers Squibb with BMS 790052, an NS5A inhibitor, and BMS 650032, an NS3 inhibitor?

IDIX: Modest insider purchase today (11/24)

John Weidenbruch, Exec VP and General Counsel, bought 20K shares at 1.89.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6623386

re: CLDX
More phase II data for CDX-110 due by April 2010. CR-011 data in December. Recent insider buying. I've been long for months and suffering through the poor reception of the CRGN merger. Good cash position and some possible near term catalysts - I'm OK with hanging in there long (5.35 basis).

NVS declines its option to license IDX 184

(bought some more at 1.98 in AH)

CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that Novartis Pharma AG has decided not to exercise its option to license IDX184, a novel liver-targeted prodrug of 2'-methyl guanosine nucleotide, for the treatment of HCV. As a result, Idenix retains the worldwide rights to develop, commercialize and license IDX184 without any further obligation to Novartis.
"As we continue to develop IDX184, we look forward to seeking a partner that will assist us in maximizing the value of this asset," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix.
About IDX184</em>
IDX184 is a novel, liver-targeted 2'-methyl guanosine nucleotide prodrug, which includes Idenix's proprietary liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing.
About Idenix</em>
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com</em>.
Forward-looking Statements </em>
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "expect," "plans," "anticipates," "will," "expects," "goal" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of IDX184, or any other product candidate and any future clinical trials involving our product candidates and expectations with respect to additional milestone payments, future royalty payments, funding of operations and future cash balances. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2008 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.
All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
Idenix Pharmaceuticals Contact:
Teri Dahlman (617) 995-9905
SOURCE Idenix Pharmaceuticals, Inc.
News Provided by Acquire Media Corporation

VNDA trading halted - pending news.

Here's news:

ROCKVILLE, Md., Oct. 12 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults. Fanapt((TM)) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist. The U.S. anti-psychotic market is approximately $14 billion.
Under the terms of the agreement, which amended and restated a prior agreement among the parties, Novartis will have exclusive commercialization rights to Fanapt(TM) for the U.S. and Canada. Novartis will be responsible for the further clinical development activities in these territories, including the development and commercialization of a long-acting injectable (or depot) formulation of Fanapt(TM). Vanda will retain rights to commercialize Fanapt(TM) oral and depot formulations outside the U.S. and Canada. At Novartis' option, the parties will enter into good faith discussions relating to an agreement for the co-commercialization of Fanapt(TM) outside of the U.S. and Canada or, alternatively, Novartis will receive a royalty on net sales.
Under the agreement, Vanda will receive an upfront payment of $200 million and will be eligible for additional payments totaling up to $265 million upon the achievement of certain development and commercial milestones for Fanapt(TM) in the U.S. and Canada. Vanda will also receive royalties on the U.S. and Canadian net sales of Fanapt(TM). The consummation of the transaction is subject to the receipt of customary regulatory approvals, which are expected by the end of 2009.
"I am very excited about our agreement with Novartis, as we now have one of the premier pharmaceutical companies in the world to commercialize the oral formulation and further develop and commercialize the depot formulation of Fanapt(TM) in the U.S. and Canada," said Mihael H. Polymeropoulos, M.D., Vanda's Chief Executive Officer. "This agreement allows Vanda to utilize current and future data generated by Novartis on the oral and depot formulations to pursue regulatory approvals outside the U.S. and Canada."
Cowen and Company, LLC acted as financial advisor to Vanda.

re: MNTA weakness

In my opinion it is just meaningless noise. The "PIPE" you keep referring to, we all know, was not a PIPE. Count me in the group that believes there will be no further need for cash raise via the capital markets.